News

Instant vaccine in the making
Enlarge image

ResearchGermany

Instant vaccine in the making

26.11.2012 - Immunologists from Germany prove that messenger RNA vaccines work in mice, ferrets and pigs. Translation to humans would speed up flu control.

The idea sounds compelling: Instead of injecting peptide parts or complete proteins to trigger immune reactions, future vaccines could consist of messenger RNA molecules. Scientists from the Friedrich-Loeffler-Institut and the biotech enterprise CureVac GmbH (both from Tübingen, Germany) as well as from a branch of Friedrich-Loeffler-Institut on an island in the Baltic Sea near Greifswald, showed that immunisation with mRNA works thus far in mice, ferrets and pigs. The corresponding study was published online on 25 November by Nature Biotechnology. Lead author Lothar Stitz from Greifwald and colleagues report that the resulting immune responses were similar or even stronger than those provoked by commercially available vaccines.

Producing conventional vaccines is a time-consuming process. If Stitz’ approach also works in humans, flu vaccines could be designed and made within weeks instead of months. Hence, pandemics could be brought under control much more easily. What is more, mRNA vaccines in general are characterised by superior stabilities at high temperatures and by improved efficacy in young and old mice. These features could make a difference as it is mostly the elderly and children who suffer most from flu casualties.

The results strengthen German Curevac GmbH, the manufacturer of mRNA-coded antigens. Only in September, the biotech set a German record by closing the biggest financing round of a German biotech ever (€80m).

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/instant-vaccine-in-the-making.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



BiologicsFinlandNetherlandsEU

26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

EPOSwitzerland

30.05.2015 Pharma giant Roche has out-licensed its anaemia drug Mircera to fellow Swiss healthcare company Galenica.

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • HYBRIGENICS (F)1.79 EUR20.13%
  • PROTHENA PLC (IE)39.44 USD14.32%
  • CELLECTIS (F)40.90 EUR11.29%

FLOP

  • ANTISOMA (UK)1.00 GBP-35.48%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • BIONOR PHARMA (N)2.19 NOK-6.01%

TOP

  • GALAPAGOS (B)52.35 EUR39.3%
  • HYBRIGENICS (F)1.79 EUR38.8%
  • CELLECTIS (F)40.90 EUR37.1%

FLOP

  • CYTOS (CH)0.64 CHF-36.6%
  • ANTISOMA (UK)1.00 GBP-35.5%
  • MEDIGENE (D)8.30 EUR-24.3%

TOP

  • CELLECTIS (F)40.90 EUR558.6%
  • WILEX (D)4.28 EUR463.2%
  • ADOCIA (F)69.50 EUR436.7%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-90.9%
  • THROMBOGENICS (B)5.34 EUR-70.1%
  • ACTIVE BIOTECH (S)10.60 SEK-68.8%

No liability assumed, Date: 01.06.2015